RT — 5mg/ 10mg/ 20mg/ 40mg

Triple-Agonist Peptide (GLP-1R / GIPR / GCGR) | Advanced Metabolic Acceleration, Energy Expenditure & Adipose Loss

Overview:
RT (Retatrutide) is a groundbreaking “Triple-G” multi-receptor agonist engineered to activate three key metabolic pathways: Glucagon-like Peptide-1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), and Glucagon (GCG) receptors. By integrating glucagon receptor activation alongside incretin mimetics, RT accelerates baseline basal metabolic rate (BMR), enhances fat oxidation, suppresses appetite, and optimizes glycemic control.

This product is supplied as a sterile lyophilized powder in 5mg, 10mg, 20mg, and 40mg multi-dose vial configurations and requires reconstitution prior to use.

First- and second-generation metabolic agonists focus solely on satiety via GLP-1 or GLP-1/GIP pathways. RT advances peptide research by adding Glucagon receptor agonism, which actively drives hepatic thermogenesis and lipid breakdown.

This triple-action mechanism ensures that calorie intake is controlled through hunger suppression while energy output is increased, resulting in unprecedented body recomposition metrics. Offered in versatile 5mg, 10mg, 20mg, and high-yield 40mg options, RT accommodates both conservative titration schedules and extended high-dose research protocols.

• Triple Receptor Agonism (GLP-1 / GIP / Glucagon): Simultaneously controls appetite, enhances insulin sensitivity, and increases baseline energy expenditure.
• Accelerated Lipolysis & Fat Burning: Direct glucagon signaling stimulates the body to mobilize and oxidize deeply stored adipose tissue.
• Powerful Appetite & Cravings Suppression: Delays gastric emptying and regulates brain satiety centers to dramatically reduce caloric intake.
• Glycemic & Metabolic Optimization: Promotes glucose clearance and improves insulin responsiveness across skeletal muscle and organ tissue.
• Multiple Vial Strengths: Flexible 5mg to 40mg vial capacities allow for easy, cost-effective dose titration over long-term research cycles.

1. Reconstitute using Bacteriostatic Water (BAC).
2. Example: Add 2.0 mL of BAC Water to a 5mg or 10mg vial, or 3.0 mL to 4.0 mL of BAC Water to 20mg and 40mg vials for manageable liquid unit concentrations.
3. Inject the BAC water slowly along the inner glass wall—do not squirt directly onto the lyophilized powder cake.
4. Gently swirl (do not shake) until the white powder dissolves completely into a clear liquid.
5. Store reconstituted RT in the refrigerator at 2°C – 8°C (36°F – 46°F) and use within 28 days.

For exact dose conversions and liquid volume planning, use our Reconstitution Calculator on the website.

Titration Starting Dose: 0.5 mg to 2.0 mg administered once weekly.

Escalation Protocol: Increase dose gradually every 4 weeks based on tolerance and target weight metrics (up to research protocol parameters).

Administration Site: Subcutaneous injection once weekly into the lower abdomen, upper thigh, or outer arm.

Protocol Duration: Cycles typically run 12 to 24+ weeks with gradual dose escalation.

Monitoring & Considerations:

• Common Considerations: Mild gastrointestinal adaptation effects such as nausea, fullness, or altered digestion (minimizing titration jumps helps prevent discomfort).
• Monitoring: Regularly check body weight composition, hydration levels, fasting glucose, and blood pressure.
• Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).